Cite
Pitt B, Steg G, Leiter LA, et al. The Role of Combined SGLT1/SGLT2 Inhibition in Reducing the Incidence of Stroke and Myocardial Infarction in Patients with Type 2 Diabetes Mellitus. Cardiovasc Drugs Ther. 2021;doi: 10.1007/s10557-021-07291-y.
Pitt, B., Steg, G., Leiter, L. A., & Bhatt, D. L. (2021). The Role of Combined SGLT1/SGLT2 Inhibition in Reducing the Incidence of Stroke and Myocardial Infarction in Patients with Type 2 Diabetes Mellitus. Cardiovascular drugs and therapy, . https://doi.org/10.1007/s10557-021-07291-y
Pitt, Bertram, et al. "The Role of Combined SGLT1/SGLT2 Inhibition in Reducing the Incidence of Stroke and Myocardial Infarction in Patients with Type 2 Diabetes Mellitus." Cardiovascular drugs and therapy vol. (2021). doi: https://doi.org/10.1007/s10557-021-07291-y
Pitt B, Steg G, Leiter LA, Bhatt DL. The Role of Combined SGLT1/SGLT2 Inhibition in Reducing the Incidence of Stroke and Myocardial Infarction in Patients with Type 2 Diabetes Mellitus. Cardiovasc Drugs Ther. 2021 Nov 09; doi: 10.1007/s10557-021-07291-y. Epub 2021 Nov 09. PMID: 34750713.
Copy
Download .nbib